Authors

Minesh Mehta, Miami Cancer InstituteFollow

NRG Oncology/RTOG1205: A Randomized Phase II Trial of Concurrent Bevacizumab and Reirradiation Versus Bevacizumab Alone as Treatment for Recurrent Glioblastoma

Publication Date

2-20-2023

Content Type

Article

PubMed ID:

36260832

Additional Authors:

Additional authors and institutional affiliations

Citation

Tsien, C. I., Pugh, S. L., Dicker, A. P., Raizer, J. J., Matuszak, M. M., Lallana, E. C., Huang, J., Algan, O., Deb, N., Portelance, L., Villano, J. L., Hamm, J. T., Oh, K. S., Ali, A. N., Kim, M. M., Lindhorst, S. M., & Mehta, M. P. (2023). NRG Oncology/RTOG1205: A Randomized Phase II Trial of Concurrent Bevacizumab and Reirradiation Versus Bevacizumab Alone as Treatment for Recurrent Glioblastoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 41(6), 1285–1295. https://doi.org/10.1200/JCO.22.00164